FR2920158B1 - Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques - Google Patents

Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques

Info

Publication number
FR2920158B1
FR2920158B1 FR0757175A FR0757175A FR2920158B1 FR 2920158 B1 FR2920158 B1 FR 2920158B1 FR 0757175 A FR0757175 A FR 0757175A FR 0757175 A FR0757175 A FR 0757175A FR 2920158 B1 FR2920158 B1 FR 2920158B1
Authority
FR
France
Prior art keywords
antibiotics
expression
recombinant proteins
cultivated cells
plasmid production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0757175A
Other languages
English (en)
Other versions
FR2920158A1 (fr
Inventor
Daniel Scherman
Corinne Marie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris 5 Rene Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris 5 Rene Descartes filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR0757175A priority Critical patent/FR2920158B1/fr
Priority to JP2010521443A priority patent/JP2010536361A/ja
Priority to CA2697498A priority patent/CA2697498A1/fr
Priority to US12/675,011 priority patent/US8440455B2/en
Priority to PCT/EP2008/061045 priority patent/WO2009027351A1/fr
Priority to EP08787440A priority patent/EP2195434A1/fr
Publication of FR2920158A1 publication Critical patent/FR2920158A1/fr
Application granted granted Critical
Publication of FR2920158B1 publication Critical patent/FR2920158B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0757175A 2007-08-24 2007-08-24 Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques Active FR2920158B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0757175A FR2920158B1 (fr) 2007-08-24 2007-08-24 Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques
JP2010521443A JP2010536361A (ja) 2007-08-24 2008-08-22 抗生物質不在下で増殖した細胞における組換え蛋白質の原形質での産生および発現
CA2697498A CA2697498A1 (fr) 2007-08-24 2008-08-22 Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques
US12/675,011 US8440455B2 (en) 2007-08-24 2008-08-22 Plasmic production and expression of recombinant proteins in cells grown without antibiotics
PCT/EP2008/061045 WO2009027351A1 (fr) 2007-08-24 2008-08-22 Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques
EP08787440A EP2195434A1 (fr) 2007-08-24 2008-08-22 Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0757175A FR2920158B1 (fr) 2007-08-24 2007-08-24 Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques

Publications (2)

Publication Number Publication Date
FR2920158A1 FR2920158A1 (fr) 2009-02-27
FR2920158B1 true FR2920158B1 (fr) 2010-03-12

Family

ID=39111557

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0757175A Active FR2920158B1 (fr) 2007-08-24 2007-08-24 Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques

Country Status (6)

Country Link
US (1) US8440455B2 (fr)
EP (1) EP2195434A1 (fr)
JP (1) JP2010536361A (fr)
CA (1) CA2697498A1 (fr)
FR (1) FR2920158B1 (fr)
WO (1) WO2009027351A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566553T3 (es) 2010-03-17 2016-04-13 Association Institut De Myologie ARNnp U7 modificados para el tratamiento de las enfermedades neuromusculares
EP2643343A1 (fr) 2010-11-26 2013-10-02 Institut Pasteur Identification d'un gyrovirus humain et applications
WO2013083753A2 (fr) 2011-12-07 2013-06-13 Institut Pasteur Identification d'un virus porcin de type paréchovirus et applications
EP2796556A1 (fr) 2013-04-25 2014-10-29 Rijksuniversiteit Groningen Moyens et procédés améliorés permettant d'exprimer des protéines de recombinaison
EP3863655A4 (fr) * 2018-10-09 2021-12-29 Second Genome, Inc. Lactococcus lactis système d'expression depour l'administration de protéines efficaces pour le traitement de troubles de la fonction barrière épithéliale
ES2933275T3 (es) 2018-12-18 2023-02-03 Neuway Pharma Gmbh Un sistema de suministro de fármacos novedoso y métodos para proporcionar los mismos
EP3670652A1 (fr) 2018-12-18 2020-06-24 NEUWAY Pharma GmbH Vlp pour le traitement d'une maladie de stockage lysosomal
CN115968403A (zh) 2020-05-22 2023-04-14 纽卫制药有限公司 用于治疗脑白质营养不良的vlp
CA3191433A1 (fr) * 2020-08-12 2022-02-17 Actym Therapeutics, Inc. Vaccins a base de bacteries immunostimulatrices, agents therapeutiques et plateformes d'administration d'arn

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (fr) * 1984-08-24 1991-10-09 The Upjohn Company Composés recombinants d'ADN et l'expression de polypeptides comme le tPA
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
IL139936A0 (en) * 1998-06-02 2002-02-10 Glaxo Group Ltd Gene therapy method

Also Published As

Publication number Publication date
FR2920158A1 (fr) 2009-02-27
US20110129487A1 (en) 2011-06-02
JP2010536361A (ja) 2010-12-02
CA2697498A1 (fr) 2009-03-05
EP2195434A1 (fr) 2010-06-16
WO2009027351A1 (fr) 2009-03-05
US8440455B2 (en) 2013-05-14

Similar Documents

Publication Publication Date Title
FR2920158B1 (fr) Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques
IL266122A (en) Stable serum-free cell-to-cell gene transfer and production of recombinant human proteins in human cell lines
IL207671A0 (en) Optimisation of expression of parvoviral rep and cap proteins in insect cells
DK2516471T4 (da) Kimære polypeptider og deres anvendelse i bakteriel dekolonisering
HRP20181315T1 (hr) Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina
IL202213A0 (en) Recombinant protein production in avian ebxr cells
DK2007884T3 (da) Cellulasefusionsproteiner og deres anvendelse
BRPI0918027A2 (pt) enzimas de lise de peptidoglicano artificial e proteínas de ligação de peptidoglicano
PL2506857T3 (pl) DOSTARCZANIE mRNA DLA ZWIĘKSZENIA ILOŚCI BIAŁEK I ENZYMÓW W LUDZKICH CHOROBACH GENETYCZNYCH
ZA201105171B (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
EP2043677A4 (fr) Combinaisons de protéines humaines destinées à accroître la viabilité de cellules souches et de cellules progénitrices
IL226771A0 (en) Recombinant elastase protein, the methods for its production and its use
EP2408926A4 (fr) Production de protéines de recombinaison dans des ciliés et leurs utilisations
HK1155772A1 (en) Expression vector for mass production of foreign gene-derived protein using animal cell and use thereof
HK1154046A1 (en) Methods and compositions for production of recombinant protein in hbx- expressing mammalian cells hbx
FR2926461B1 (fr) Nouveau facteur de croissance cellulaire d'origine non animale et applications
EP2154251A4 (fr) Système d'expression de protéine recombinante à rendement et immunogénicité améliorés
IL207174A (en) An isolated peptide capable of stimulating the production of one or more extracellular matrix proteins in fibroblast cells, its pharmacological composition and its use
FR2943062B1 (fr) Nouveau peptide promoteur de l'adhesion et de la migration cellulaire
HK1250241A1 (zh) 細小病毒rep和cap蛋白在昆蟲細胞中的表達優化

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

CD Change of name or company name

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20221006

Owner name: UNIVERSITE PARIS CITE, FR

Effective date: 20221006

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -, FR

Effective date: 20221006

PLFP Fee payment

Year of fee payment: 17